Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake

Abstract

We examined the relationship between in vivo estimates of tau deposition as measured by ¹⁸F-AV-1451 tau positron emission tomography imaging and cross-sectional cortical thickness, as well as rates of antecedent cortical thinning measured from magnetic resonance imaging in individuals with and without evidence of cerebral amyloid in 63 participants from the Alzheimer's Disease Neuroimaging Initiative study, including 32 cognitively normal individuals (mean age 74 years), 27 patients with mild cognitive impairment (mean age 76.8 years), and 4 patients diagnosed with Alzheimer's disease (mean age 80 years). We hypothesized that structural measures would correlate with ¹⁸F-AV-1451 in a spatially local manner and that this correlation would be stronger for longitudinal compared to cross-sectional measures of cortical thickness and in those with cerebral amyloid versus those without. Cross-sectional and longitudinal estimates of voxelwise atrophy were made from whole brain maps of cortical thickness and rates of thickness change. In amyloid-β–positive individuals, the correlation of voxelwise atrophy across the whole brain with a summary measure of medial temporal lobe (MTL) ¹⁸F-AV-1451 uptake demonstrated strong local correlations in the MTL with longitudinal atrophy that was weaker in cross-sectional analysis. Similar effects were seen in correlations between 31 bilateral cortical regions of interest. In addition, several nonlocal correlations between atrophy and ¹⁸F-AV-1451 uptake were observed, including association between MTL atrophy and ¹⁸F-AV-1451 uptake in parietal lobe regions of interest such as the precuneus. Amyloid-β–negative individuals only showed weaker correlations in data uncorrected for multiple comparisons. While these data replicate previous reports of associations between ¹⁸F-AV-1451 uptake and cross-sectional structural measures, the current results demonstrate a strong relationship with longitudinal measures of atrophy. These data support the notion that in vivo measures of tau pathology are tightly linked to the rate of neurodegenerative change.

Introduction

Deposition of paired helical filament tau neurofibrillary tangles (NFTs) along with accumulation of amyloid-β (Aβ) plaques is a hallmark pathology of Alzheimer's disease (AD) (Hyman and Trojanowski, 1997). Ex vivo studies have shown clear associations between NFT burden and antemortem patterns of gray matter atrophy measured by magnetic resonance imaging (MRI) in AD (Whitwell et al., 2008, Whitwell et al., 2012). Recent advances in molecular imaging have made it possible to quantify regional tau burden in vivo (Saint-Aubert et al., 2017). ¹⁸F-AV-1451 is a positron emission tomography (PET) tracer that has been used to measure tau deposition due to its selective binding to certain insoluble forms of tau in paired helical filaments (Marquié et al., 2015). ¹⁸F-AV-1451 tau tracer uptake has been reported to broadly replicate patterns of NFT deposition based on widely used neuropathological stages (i.e., Braak stages) of AD defined by autopsy studies (Braak and Braak, 1991, Braak and Braak, 1996)—beginning in medial temporal lobe (MTL), advancing to lateral temporal lobe, inferior frontal, midline and inferior parietal regions, and finally to primary sensorimotor cortices in the latter stages (Cho et al., 2016a, Johnson et al., 2016, Schwarz et al., 2016, Schöll et al., 2016). To the extent that NFT pathology is responsible for downstream neurodegeneration across the disease spectrum and that ¹⁸F-AV-1451 binds to AD-related species of tau, structural MRI, an established measure of AD-related neurodegeneration, should be correlated with tracer uptake. Indeed, there are a few reports in which quantitative structural measures have been found to be associated with specific spatial patterns of tau deposition measured using ¹⁸F-AV-1451 tau tracer uptake, similar to those observed in pathology studies (Wang et al., 2016, Xia et al., 2017). While there is emerging data with regard to the spatial correlation of ¹⁸F-AV-1451 uptake with both local and distant cross-sectional structural measures (Dronse et al., 2017, Golla et al., 2017, Iaccarino et al., 2018, Lockhart et al., 2017, Ossenkoppele et al., 2016, Rafii et al., 2017, Schöll et al., 2016, Sepulcre et al., 2016, Vemuri et al., 2017), the extent of these relationships remains far from clearly delineated. Furthermore, longitudinal atrophy rates, a more direct measure of the dynamic process of neurodegeneration, have not been studied in the context of tau accumulation across the AD continuum, although 1 study reported local and distant correlations of tau burden and retrospective longitudinal atrophy in a cohort consisting of only cognitively normal individuals (LaPoint et al., 2017). Finally, the significance and association of ¹⁸F-AV-1451 PET with atrophy in Aβ-negative control subjects is uncertain.

In this study, we aimed to extend work on relationships between ¹⁸F-AV-1451 tau tracer uptake and atrophy by investigating longitudinal measures of atrophy. We hypothesized that in a cohort of Aβ-positive individuals that includes both asymptomatic and symptomatic subjects (both mild cognitive impairment [MCI] and AD), the association of local tau deposition in MTL will be stronger with a longitudinal than cross-sectional measure of atrophy, as this would better reflect an active neurodegenerative process specific to tau pathology. If ¹⁸F-AV-1451 PET is sensitive to the NFT pathology associated with aging in the absence of cerebral amyloid, so-called primary age-related tauopathy (PART), and this pathology has downstream neurodegenerative effects, we would also expect correlation of ¹⁸F-AV-1451 uptake with structural measures in Aβ-negative individuals, but likely circumscribed to early Braak regions.

We studied structural MRI and ¹⁸F-AV-1451 PET imaging data in 63 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We correlated a summary measure of ¹⁸F-AV-1451 tau tracer uptake in the MTL with cortical thickness–based measures of both cross-sectional and longitudinal atrophies at each voxel in the cortical gray matter. We chose to focus on MTL tracer uptake in a region encompassing perirhinal (including transentorhinal cortex) and entorhinal cortices as these are the earliest regions of NFT deposition, given the significant proportion of individuals who were cognitively normal in this cohort and, thus, likely at early disease stage. More broadly, we conducted a cross-modality pairwise correlation analysis in both cross-sectional and longitudinal data between ¹⁸F-AV-1451 tau tracer uptake and atrophy across 31 bilateral regions of interest (ROIs) in the cortex. We performed these analyses separately in Aβ-positive and Aβ-negative groups, as determined by their amyloid PET scans.